RxDoctor Payments Data

Ismael Diaz, MD

Family Medicine · Humble, TXNPI 1831187004

Payments from drug & device makers

$10,257in general payments, 2019–2025

Across 459 payments — averaging $22.35 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$2K
  • AstraZeneca$1K
  • Biohaven Pharmaceuticals, Inc.$1K
  • Lilly USA, LLC$706
  • Bayer$614
  • Sanofi-aventis U.S. LLC$584
  • plus $4K from 47 others

What the payments were for

  • Consulting fees$1,20012%
  • Food & beverage$9,05488%
  • Education$30%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$10,257 in reported general payments places this provider in the 90th percentile of 8,760 family medicine providers in Texas.

See all family medicine providers in Texas

Medicare billing

Part B allowed, 2024
$173,369
Medicare patients
368
Services billed
3,712

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide160$235,290
JardianceEmpagliflozin88$108,843
MounjaroTirzepatide55$71,726
TrulicityDulaglutide48$59,649
FarxigaDapagliflozin Propanediol48$45,604
JanuviaSitagliptin Phosphate19$30,456
JanumetSitagliptin Phos/Metformin Hcl20$29,309
ProliaDenosumab17$29,289
EliquisApixaban16$20,496
Soliqua 100-33Insulin Glargine/Lixisenatide15$13,321
Trelegy ElliptaFluticasone/Umeclidin/Vilanter15$12,859
Rosuvastatin Calcium623$8,788
Gabapentin262$5,166
Atorvastatin Calcium469$4,962
PremarinEstrogens, Conjugated20$3,726

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$1,645$235,290160 claims
Lilly USA, LLCMounjaro, Trulicity$706$131,375103 claims
Boehringer IngelheimJardiance$247$108,84388 claims
MerckJanuvia, Janumet$170$59,76539 claims
AstraZenecaFarxiga$1,351$45,60448 claims
AmgenProlia$132$29,28917 claims
PfizerEliquis, Premarin$171$24,22236 claims
Sanofi-aventis U.S. LLCSoliqua 100-33$584$13,32115 claims
GSKTrelegy Ellipta$230$12,85915 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium$34$2,616306 claims
AbbVieSynthroid$566$1,92424 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 8,760 family medicine providers in Texas.

Other family medicine in Humble

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →